CoChat

Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers

Open access

Published version of a preprint

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.

Abstract

Minor splicing is an under-appreciated splicing system required for the correct expression of ~700 genes in the human genome. This small subset of genes (0.35%) harbours introns containing non-canonical splicing sequences that are recognised uniquely by the minor spliceosome and cannot be processed by the major spliceosome. Using in vivo zebrafish and mouse cancer models, we show that heterozygous expression of Rnpc3 , encoding a unique protein component of the minor spliceosome, restricts the growth and survival of liver, lung and gastric tumours without impacting healthy cells. RNPC3 knockdown in human lung cancer-derived A549 cells also impairs cell proliferation and RNA-seq analysis reveals a robust and selective disruption to minor intron splicing and transcription-wide effects on gene expression. We further demonstrate that these perturbations are accompanied by DNA replication stress, DNA damage, accumulation of TP53 protein and activation of a Tp53-dependent transcriptional program that induces cell cycle arrest and apoptosis. Together our data reveal a vulnerability of cancer cells to minor splicing inhibition that restricts tumour growth.

Overview

CoChat Summary

TL;DR

Heterozygous loss or knockdown of the minor spliceosome component RNPC3/65K restricts growth and survival of liver, lung, gastric, and AML cancers in zebrafish and mouse models, largely without affecting healthy tissues. In A549 lung cancer cells, impaired minor splicing causes minor intron retention/alternative splicing, DNA replication stress and damage, TP53 stabilization, and a TP53-dependent program of cell cycle arrest, senescence, and apoptosis.

Key findings

  • In a zebrafish krasG12V HCC model, rnpc3 heterozygosity reduced dox-induced liver enlargement from >5-fold to threefold, lowered adult liver/body weight from >12% to 7%, reduced EdU-positive hepatocytes from ~31% to 19% (40% reduction), and increased AnnexinV-mKate apoptotic foci by 40%.
  • The zebrafish HCC effect depended on Tp53: rnpc3 heterozygosity reduced liver volume by 40% with WT tp53 but only 8% without functional Tp53; γ-H2AX-positive hepatocytes rose from 0.8% (WT/WT) to 4% in rnpc3 HETs and to 12.7% in rnpc3 HETs lacking WT Tp53.
  • In mouse models, Rnpc3 heterozygosity reduced KrasG12D-driven lung tumor burden and Gp130F/F gastric adenoma weight at 100 and 180 days; ~40% of Rnpc3+/−;Gp130F/F mice had no corpus adenomas at 100 days, and pERK1/2 was decreased by 35%. In MLL-ENL AML, Rnpc3 recombination caused 95% loss of Rnpc3 mRNA, increased minor intron retention, and extended median survival by 52% (19 to 29 days) and 55% (22 to 34 days).
  • In A549 cells, RNPC3 knockdown (~70%) reduced confluency by 30%; RNA-seq found 158/389 detected minor introns (40.6%) aberrantly spliced, with 134 (34.4%) elevated intron retention, 14 (3.6%) alternative splicing, and 10 (2.6%) both. IRFinder showed 60/599 minor introns (10%) with increased retention versus 148/179,463 major introns (0.08%), and U12 ASO caused a fivefold increase in γH2AX-positive cells, threefold more senescence, and G2 accumulation.

Methods

  • In vivo cancer models: zebrafish TO(krasG12V) HCC with rnpc3 and tp53 genotypes, mouse KrasLSLG12D lung adenocarcinoma induced by intranasal AdCre, Gp130F/F gastric adenoma model with Tff1-CreERT2-induced Rnpc3 recombination, and MLL-ENL-GFP retroviral AML model using Rnpc3lox/lox;UBC-CreERT2 cells.
  • In vitro human model: A549 lung adenocarcinoma cells transfected with RNPC3 or PDCD7 siRNAs or U12 ASO; assays included RT-qPCR/RT-PCR, RNA-seq, IRFinder, IPA, FACS for cell cycle/DNA damage/senescence, immunoblotting, and live-cell confluency.
  • Statistics: Student’s t tests with Welch’s correction, one-way/two-way ANOVA with Tukey’s or Dunnett’s tests, Mantel–Cox for survival, and FDR control for RNA-seq; data generally shown as mean ± SEM.

Limitations

  • The paper states that its multifaceted approach had disadvantages: focusing on fewer in vivo models might have demonstrated a formal link between Rnpc3 heterozygosity and aberrant minor splicing, which is absent from the current study.
  • The paper states that in vivo gene dosing could only be reduced genetically by 50% or 100% (or not at all), making clinical extrapolation difficult; it predicts a therapeutic dose of RNPC3/65K inhibition would lie within the 50–100% range.
  • The paper states that RNA-seq did not provide definitive evidence that mis-splicing of BRAF/RAF1/MAPK transcripts is responsible for decreased A549 growth/survival; evident from the text, the mechanistic work relies heavily on one human cell line (A549), and no small-molecule minor spliceosome inhibitor or patient-derived tumor data are presented.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s44319-025-00511-8

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
CC BY · PubMed Central
Image 2
CC BY · PubMed Central
Figure 1 Heterozygous loss of rnpc3 reduces tumour burden in a krasG12V-driven zebrafish model of hepatocellular carcinoma (HCC). (A) RT-qPCR analysis of rnpc3 mRNA extracted from independent pools of rnpc3+/− larvae aged 7 days post-fertilization (dpf) compared to rnpc3+/+ larvae (n = 3 biological replicates). (B) Representative Imaris three-dimensional reconstructions of 2-CLiP and dox-treated TO(krasG12V)T/+ livers of 7 dpf larvae of the indicated rnpc3 genotype. Scale bar is 25 µm. (C) Liver volume in 2-CLiP (red symbols, n = 26 or n = 29) and TO(krasG12V) transgene (green circles, n = 24 or n = 28) zebrafish at 7 dpf. Black arrows on the graphs indicate the data points (black symbols) that correspond to the representative images shown in (B). (D, E) EdU (white dots) and Hoechst 33342-positive hepatocyte nuclei (n = 11) at 7 dpf. Black arrows on the graphs indicate the data points that correspond to the representative images shown in (D). Scale bar is 50 μm. (F, G) Foci of AnnexinV-mKate fluorescence in TO(krasG12V) livers (n = 19 and 20) at 7 dpf. Black arrows on the graphs indicate the data points that correspond to the representative images shown in (F). Scale bar is 50 μm. Data are represented as mean ± SEM. Significance was assessed using a Student’s t test, P < 0.05. Source data are available online for this figure.
Figure 1 Heterozygous loss of rnpc3 reduces tumour burden in a krasG12V-driven zebrafish model of hepatocellular carcinoma (HCC). (A) RT-qPCR analysis of rnpc3 mRNA extracted from independent pools of rnpc3+/− larvae aged 7 days post-fertilization (dpf) compared to rnpc3+/+ larvae (n = 3 biological replicates). (B) Representative Imaris three-dimensional reconstructions of 2-CLiP and dox-treated TO(krasG12V)T/+ livers of 7 dpf larvae of the indicated rnpc3 genotype. Scale bar is 25 µm. (C) Liver volume in 2-CLiP (red symbols, n = 26 or n = 29) and TO(krasG12V) transgene (green circles, n = 24 or n = 28) zebrafish at 7 dpf. Black arrows on the graphs indicate the data points (black symbols) that correspond to the representative images shown in (B). (D, E) EdU (white dots) and Hoechst 33342-positive hepatocyte nuclei (n = 11) at 7 dpf. Black arrows on the graphs indicate the data points that correspond to the representative images shown in (D). Scale bar is 50 μm. (F, G) Foci of AnnexinV-mKate fluorescence in TO(krasG12V) livers (n = 19 and 20) at 7 dpf. Black arrows on the graphs indicate the data points that correspond to the representative images shown in (F). Scale bar is 50 μm. Data are represented as mean ± SEM. Significance was assessed using a Student’s t test, P < 0.05. Source data are available online for this figure.CC BY · PubMed Central
Figure EV1 Heterozygous loss of rnpc3 reduces tumour burden in a krasG12V-driven zebrafish model of hepatocellular carcinoma (HCC). (A) Western blot of active Ras-GTP protein following active Ras pull-down from TO(krasG12V) larvae of the indicated rnpc3 genotype. (B) rnpc3+/+ and rnpc3+/− liver/body mass ratio (%) of adult male TO(krasG12V) (3.5–4 months of age) with and without dox treatment. n = 20, 2 pooled independent experiments. Mean ± SEM, significance was assessed by one-way ANOVA with Tukey’s multiple comparison test.
Figure EV1 Heterozygous loss of rnpc3 reduces tumour burden in a krasG12V-driven zebrafish model of hepatocellular carcinoma (HCC). (A) Western blot of active Ras-GTP protein following active Ras pull-down from TO(krasG12V) larvae of the indicated rnpc3 genotype. (B) rnpc3+/+ and rnpc3+/− liver/body mass ratio (%) of adult male TO(krasG12V) (3.5–4 months of age) with and without dox treatment. n = 20, 2 pooled independent experiments. Mean ± SEM, significance was assessed by one-way ANOVA with Tukey’s multiple comparison test.CC BY · PubMed Central
Figure 2 rnpc3 heterozygosity combines with krasG12V to activate a Tp53 DNA damage response that restricts tumour burden. (A) Tp53 Western blot in lysates of 7 dpf TO(krasG12V) larvae of the indicated rnpc3 genotype. Values shown are normalized by reference to the Gapdh loading control and compared with the Tp53 signal in lane 3, which was set at 1. (B) Representative three-dimensional reconstructions of 7 dpf TO(krasG12V)T/+ livers of the indicated rnpc3 and tp53 genotypes. Scale bar is 25 µm. (C) Impact of rnpc3 heterozygosity and homozygous tp53 mutation on liver volume in 7 dpf TO(krasG12V)T/+ larvae. Data represented as mean ± SEM, n = 28, 32, 27 and 24. Significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. Scale bar is 25 µm. (D–K) RT-qPCR analysis of gene expression in 7 dpf TO(krasG12V)T/+ dissected livers of the indicated rnpc3 and tp53 genotypes. Data are expressed as mean ± SEM, n = 3 biological replicates. (L) Representative Airyscan imaging of liver cryosections of liver from 7 dpf TO(krasG12V)T/+ larvae of the indicated rnpc3 and tp53 genotype stained with γ-H2AX antibody (white) marking DNA double-strand breaks, DAPI (cyan) marking DNA, and EGFP-KrasG12V (magenta) marking the cell membrane. Scale bar is 5 µm. (M) Quantification of the percentage of hepatocytes positive for γ-H2AX. Data are expressed as mean ± SEM, n = 32, 47, 46 and 30. Significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. Source data are available online for this figure.
Figure 2 rnpc3 heterozygosity combines with krasG12V to activate a Tp53 DNA damage response that restricts tumour burden. (A) Tp53 Western blot in lysates of 7 dpf TO(krasG12V) larvae of the indicated rnpc3 genotype. Values shown are normalized by reference to the Gapdh loading control and compared with the Tp53 signal in lane 3, which was set at 1. (B) Representative three-dimensional reconstructions of 7 dpf TO(krasG12V)T/+ livers of the indicated rnpc3 and tp53 genotypes. Scale bar is 25 µm. (C) Impact of rnpc3 heterozygosity and homozygous tp53 mutation on liver volume in 7 dpf TO(krasG12V)T/+ larvae. Data represented as mean ± SEM, n = 28, 32, 27 and 24. Significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. Scale bar is 25 µm. (D–K) RT-qPCR analysis of gene expression in 7 dpf TO(krasG12V)T/+ dissected livers of the indicated rnpc3 and tp53 genotypes. Data are expressed as mean ± SEM, n = 3 biological replicates. (L) Representative Airyscan imaging of liver cryosections of liver from 7 dpf TO(krasG12V)T/+ larvae of the indicated rnpc3 and tp53 genotype stained with γ-H2AX antibody (white) marking DNA double-strand breaks, DAPI (cyan) marking DNA, and EGFP-KrasG12V (magenta) marking the cell membrane. Scale bar is 5 µm. (M) Quantification of the percentage of hepatocytes positive for γ-H2AX. Data are expressed as mean ± SEM, n = 32, 47, 46 and 30. Significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. Source data are available online for this figure.CC BY · PubMed Central
Figure 3 Rnpc3 heterozygosity reduces tumour burden in a mouse model of lung adenocarcinoma and gastric adenoma. (A) RT-qPCR analysis of Rnpc3 mRNA extracted from 160-day-old WT and Rnpc3 heterozygous mouse stomach and lung tissue (n = 4, 2 males and 2 females). Results are expressed as mean ± SEM. Significance was assessed using multiple unpaired t tests. (B, C) Representative hematoxylin and eosin-stained lung sections 180 days after intranasal administration of adenoviral Cre recombinase (AdCre). Arrows and arrowhead indicate foci of atypical adenomatous hyperplasia (AAH) and adenoma, respectively. These lesions are pERK and 65 K positive. Scale bar in (B, C) is 2 mm. Scale bar in (B′, C′) is 200 μm. (D) Quantification of hyperplasia in sections of lung, expressed as a percentage of total lung area. Results are expressed as mean ± SEM, n = 5 or 7 per genotype. Significance was assessed using a Student’s t test. (E) Representative adenomas in the corpus (arrowhead) and antral (arrow) regions of the glandular stomach of mice. Scale bar is 5 mm. (F) Total adenoma weight at 100 d of age, n = 20 or 21 per genotype. Data are expressed as mean ± SEM. (G) Total adenoma weight at 180 d of age, n = 10 or 14 per genotype. Data are expressed as mean ± SEM. Significance was assessed with a Student’s t test with Welch’s correction. (H) Histological sections of the glandular stomach stained with H&E at 100 d. (I) Immunocytochemical localization of pERK1/2 indicates active MAPK signalling at the luminal surface of adenomas in 100 d old Gp130F/F mice. Scale bar in (H, I) is 2 mm. (J) Western blot analysis of pERK1/2 proteins in antral adenomas from four individual mice/genotype at 100 d. Values shown are normalized by reference to the α-tubulin loading control and relative to Rnpc3+/+; Gp130F/F samples. (K) Quantification of pERK1/2 protein abundance shown in (J). Data are expressed as mean ± SEM, n = 4. Significance was assessed with a Student’s t test. Source data are available online for this figure.
Figure 3 Rnpc3 heterozygosity reduces tumour burden in a mouse model of lung adenocarcinoma and gastric adenoma. (A) RT-qPCR analysis of Rnpc3 mRNA extracted from 160-day-old WT and Rnpc3 heterozygous mouse stomach and lung tissue (n = 4, 2 males and 2 females). Results are expressed as mean ± SEM. Significance was assessed using multiple unpaired t tests. (B, C) Representative hematoxylin and eosin-stained lung sections 180 days after intranasal administration of adenoviral Cre recombinase (AdCre). Arrows and arrowhead indicate foci of atypical adenomatous hyperplasia (AAH) and adenoma, respectively. These lesions are pERK and 65 K positive. Scale bar in (B, C) is 2 mm. Scale bar in (B′, C′) is 200 μm. (D) Quantification of hyperplasia in sections of lung, expressed as a percentage of total lung area. Results are expressed as mean ± SEM, n = 5 or 7 per genotype. Significance was assessed using a Student’s t test. (E) Representative adenomas in the corpus (arrowhead) and antral (arrow) regions of the glandular stomach of mice. Scale bar is 5 mm. (F) Total adenoma weight at 100 d of age, n = 20 or 21 per genotype. Data are expressed as mean ± SEM. (G) Total adenoma weight at 180 d of age, n = 10 or 14 per genotype. Data are expressed as mean ± SEM. Significance was assessed with a Student’s t test with Welch’s correction. (H) Histological sections of the glandular stomach stained with H&E at 100 d. (I) Immunocytochemical localization of pERK1/2 indicates active MAPK signalling at the luminal surface of adenomas in 100 d old Gp130F/F mice. Scale bar in (H, I) is 2 mm. (J) Western blot analysis of pERK1/2 proteins in antral adenomas from four individual mice/genotype at 100 d. Values shown are normalized by reference to the α-tubulin loading control and relative to Rnpc3+/+; Gp130F/F samples. (K) Quantification of pERK1/2 protein abundance shown in (J). Data are expressed as mean ± SEM, n = 4. Significance was assessed with a Student’s t test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV2 Recombination of Rnpc3lox alleles in mice reduces tumour burden in KrasG12D-driven lung adenocarcinoma and a Gp130F/F gastric adenoma model. (A, B) Histological analysis of lung hyperplasia. Areas of AAH (atypical adenomatous hyperplasia; arrows) and bronchial hyperplasia (arrowheads) were observed in the lungs 90 d after adenoviral Cre recombinase administration. Scale bar is 2 mm. (A’, B’) Higher magnification images of region in dashed box. Scale bar is 200 μm. (C, D) Quantitation of the frequency and area of the hyperplastic lesions. Data are expressed as mean ± SEM, n = 10 or 14 per genotype. Significance was assessed using an unpaired Student’s t test with Welch’s correction. (E) Schematic diagram of gastric adenoma formation in Gp130F/F mice and treatment with tamoxifen (2 x TMX) on days 56 and 57 (red arrows) to induce recombination of Rnpc3lox alleles. (F) Representative stomachs with adenomas in the corpus (arrowhead) and antrum (arrow). Scale bar is 5 mm. (G) Quantitation of adenoma weight. Data are expressed as mean ± SEM, n = 6 or 10 per genotype. Significance was assessed using an unpaired Student’s t test with Welch’s correction. (H) RT-qPCR analysis of Rnpc3 mRNA in single antral adenomas from three independent mice per genotype. Data are expressed as mean ± SEM. Significance was evaluated with a two-tailed Student’s t test. (I) PCR of genomic DNA for Rnpc3 alleles in normal glandular stomach and adenomas harvested from TMX-treated, Tff1-CreERT2;Rnpc3lox/lox;Gp130F/F mice, n = 3.
Figure EV2 Recombination of Rnpc3lox alleles in mice reduces tumour burden in KrasG12D-driven lung adenocarcinoma and a Gp130F/F gastric adenoma model. (A, B) Histological analysis of lung hyperplasia. Areas of AAH (atypical adenomatous hyperplasia; arrows) and bronchial hyperplasia (arrowheads) were observed in the lungs 90 d after adenoviral Cre recombinase administration. Scale bar is 2 mm. (A’, B’) Higher magnification images of region in dashed box. Scale bar is 200 μm. (C, D) Quantitation of the frequency and area of the hyperplastic lesions. Data are expressed as mean ± SEM, n = 10 or 14 per genotype. Significance was assessed using an unpaired Student’s t test with Welch’s correction. (E) Schematic diagram of gastric adenoma formation in Gp130F/F mice and treatment with tamoxifen (2 x TMX) on days 56 and 57 (red arrows) to induce recombination of Rnpc3lox alleles. (F) Representative stomachs with adenomas in the corpus (arrowhead) and antrum (arrow). Scale bar is 5 mm. (G) Quantitation of adenoma weight. Data are expressed as mean ± SEM, n = 6 or 10 per genotype. Significance was assessed using an unpaired Student’s t test with Welch’s correction. (H) RT-qPCR analysis of Rnpc3 mRNA in single antral adenomas from three independent mice per genotype. Data are expressed as mean ± SEM. Significance was evaluated with a two-tailed Student’s t test. (I) PCR of genomic DNA for Rnpc3 alleles in normal glandular stomach and adenomas harvested from TMX-treated, Tff1-CreERT2;Rnpc3lox/lox;Gp130F/F mice, n = 3.CC BY · PubMed Central
Figure 4 Disruption of the Rnpc3 locus in AML cells causes impaired minor splicing and prolonged survival of mice. (A) Schematic diagram depicting the AML experimental workflow. (B) PCR for Rnpc3 recombination on AML cells treated in vitro for 72 h with 4-OHT. L Ladder. (C) RT-qPCR of Rnpc3 transcripts on AML cells treated in vitro for 72 h with 4-OHT. Data are expressed as mean ± SEM, n = 3. (D) RT-qPCR of amplicons containing retained minor introns. Results are expressed as the mean of three independent secondary AML cell lines per genotype ± SEM, significance was assessed using a two-tailed, unpaired Students’ t test, except for Parp1, Vps16 and Mapk1 where n = 2. (E) Kaplan–Meier plot of female mice harbouring tertiary transplants of Rnpc3lox/lox;UBC-CreERT2 AML cells, treated with TMX or vehicle 13 and 14 days later (n = 6 and 3, respectively, one experiment). (F) Kaplan–Meier plot of female mice harbouring tertiary transplants of Rnpc3lox/−;UBC-CreERT2 AML cells, treated with TMX or vehicle 13 and 14 days later. (n = 15 and 11, respectively, two independent experiments combined). Significance was assessed with a Mantel–Cox test. Source data are available online for this figure.
Figure 4 Disruption of the Rnpc3 locus in AML cells causes impaired minor splicing and prolonged survival of mice. (A) Schematic diagram depicting the AML experimental workflow. (B) PCR for Rnpc3 recombination on AML cells treated in vitro for 72 h with 4-OHT. L Ladder. (C) RT-qPCR of Rnpc3 transcripts on AML cells treated in vitro for 72 h with 4-OHT. Data are expressed as mean ± SEM, n = 3. (D) RT-qPCR of amplicons containing retained minor introns. Results are expressed as the mean of three independent secondary AML cell lines per genotype ± SEM, significance was assessed using a two-tailed, unpaired Students’ t test, except for Parp1, Vps16 and Mapk1 where n = 2. (E) Kaplan–Meier plot of female mice harbouring tertiary transplants of Rnpc3lox/lox;UBC-CreERT2 AML cells, treated with TMX or vehicle 13 and 14 days later (n = 6 and 3, respectively, one experiment). (F) Kaplan–Meier plot of female mice harbouring tertiary transplants of Rnpc3lox/−;UBC-CreERT2 AML cells, treated with TMX or vehicle 13 and 14 days later. (n = 15 and 11, respectively, two independent experiments combined). Significance was assessed with a Mantel–Cox test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV3 Recombination of the Rnpc3 locus in MLL-ENL AML cells in vitro reduces cell viability. (A) Representative fluorescence-activated cell sorting (FACS) plots of cell viability using AnnexinV and PI staining. Numbers in each quadrant indicate the percentage of cells in each category. (B) Quantitation of the percentage of viable (AnnexinV−, PI−) cells over time enumerated by FACS. Percentage viable cells expressed as mean ± SEM, n = 3 for all cohorts. Significant differences were assessed with a one-way ANOVA with Tukey’s multiple comparison test. (C) Kaplan–Meier survival plot of mice harbouring tertiary transplants of MLL-ENL AML cells with all control genotypes in the presence (solid line) and absence (dotted line) of TMX treatment 13 and 14 d (black arrows) following transplantation. There is no significant difference in median survival (19–23 d) between all control cohorts (i.e. no Rnpc3lox alleles and no TMX treatment), n = 311. Significance was assessed with a Mantel–Cox test. (D) Spleen from a WT mouse not transplanted with AML cells next to a spleen harvested from a mouse transplanted with UBC-CreERT2;Rnpc3lox/lox AML cells and treated with TMX. (E) Example FACS analysis of UBC-CreERT2;Rnpc3lox/lox AML cells. (F) Genomic analysis of the Rnpc3 locus in tertiary transplanted AML cells.
Figure EV3 Recombination of the Rnpc3 locus in MLL-ENL AML cells in vitro reduces cell viability. (A) Representative fluorescence-activated cell sorting (FACS) plots of cell viability using AnnexinV and PI staining. Numbers in each quadrant indicate the percentage of cells in each category. (B) Quantitation of the percentage of viable (AnnexinV−, PI−) cells over time enumerated by FACS. Percentage viable cells expressed as mean ± SEM, n = 3 for all cohorts. Significant differences were assessed with a one-way ANOVA with Tukey’s multiple comparison test. (C) Kaplan–Meier survival plot of mice harbouring tertiary transplants of MLL-ENL AML cells with all control genotypes in the presence (solid line) and absence (dotted line) of TMX treatment 13 and 14 d (black arrows) following transplantation. There is no significant difference in median survival (19–23 d) between all control cohorts (i.e. no Rnpc3lox alleles and no TMX treatment), n = 311. Significance was assessed with a Mantel–Cox test. (D) Spleen from a WT mouse not transplanted with AML cells next to a spleen harvested from a mouse transplanted with UBC-CreERT2;Rnpc3lox/lox AML cells and treated with TMX. (E) Example FACS analysis of UBC-CreERT2;Rnpc3lox/lox AML cells. (F) Genomic analysis of the Rnpc3 locus in tertiary transplanted AML cells.CC BY · PubMed Central
Figure 5 RNPC3 knockdown impairs the growth of A549 cells and causes defects in the splicing of minor introns resulting in differential expression of genes enriched in cancer related pathways. (A) RT-qPCR analysis of RNPC3 transcripts in A549 cells treated with siRNPC3 #18 and #19 for 72 h. Data are represented as mean ± SEM (n = 4 biological replicates). (B) Quantification of A549 cell growth over 72 h treatment with non-targeting (NT) or 2 independent RNPC3 siRNAs. Data are represented as mean ± SEM (n = 3, 25 images per well, every hour). Significance was assessed by two-way ANOVA with Dunnett’s multiple comparisons test. (C) Pie chart displaying percentage distribution of aberrant minor intron splicing events in siRNPC3-treated cells. (D) Volcano plot of MIG transcripts exhibiting significant minor intron retention (solid red circles) in siRNPC3-treated cells. Significance was assessed by Welch’s t test. For an intron to be called as significantly retained in siRNPC3 samples, we required the following, FDR ≦ 0.05, 100% coverage of the intron in siRNPC3 samples, ≥10% IRratio in siRNPC3 and ≥ 5% IRratio over siNT samples. Likewise, for an intron to be significantly retained in siNT samples, FDR ≦ 0.05, 100% coverage across the intron in siNT samples, ≥ 10% IRratio in siNT cells and ≥ 5% IRratio over siRNPC3 samples (n = 4 replicates per genotype). (E) Example RNAseq read coverage plots showing RNPC3 knockdown increases minor intron retention in MAPK12 and ATG3 and produces alternative splicing in NAA60 and VPS35. (F) Scatter plot of differential gene expression between siRNPC3 and siNT-treated A549 cells. Of the 24,061 expressed transcripts, 2268 are DEGs (1286 downregulated shown in blue, 985 upregulated shown in red. The dysregulated MIGs are circled in yellow). (G) Differential gene expression analysis of MIGs compared to all transcripts. (H) Selection of significantly enriched canonical pathways identified by IPA analysis of all affected genes (DEGs plus IR and AS affected MIGs). -log (P) values > 1.3 (vertical line) signify significant enrichment. Significance was assessed by Fisher exact test. Source data are available online for this figure.
Figure 5 RNPC3 knockdown impairs the growth of A549 cells and causes defects in the splicing of minor introns resulting in differential expression of genes enriched in cancer related pathways. (A) RT-qPCR analysis of RNPC3 transcripts in A549 cells treated with siRNPC3 #18 and #19 for 72 h. Data are represented as mean ± SEM (n = 4 biological replicates). (B) Quantification of A549 cell growth over 72 h treatment with non-targeting (NT) or 2 independent RNPC3 siRNAs. Data are represented as mean ± SEM (n = 3, 25 images per well, every hour). Significance was assessed by two-way ANOVA with Dunnett’s multiple comparisons test. (C) Pie chart displaying percentage distribution of aberrant minor intron splicing events in siRNPC3-treated cells. (D) Volcano plot of MIG transcripts exhibiting significant minor intron retention (solid red circles) in siRNPC3-treated cells. Significance was assessed by Welch’s t test. For an intron to be called as significantly retained in siRNPC3 samples, we required the following, FDR ≦ 0.05, 100% coverage of the intron in siRNPC3 samples, ≥10% IRratio in siRNPC3 and ≥ 5% IRratio over siNT samples. Likewise, for an intron to be significantly retained in siNT samples, FDR ≦ 0.05, 100% coverage across the intron in siNT samples, ≥ 10% IRratio in siNT cells and ≥ 5% IRratio over siRNPC3 samples (n = 4 replicates per genotype). (E) Example RNAseq read coverage plots showing RNPC3 knockdown increases minor intron retention in MAPK12 and ATG3 and produces alternative splicing in NAA60 and VPS35. (F) Scatter plot of differential gene expression between siRNPC3 and siNT-treated A549 cells. Of the 24,061 expressed transcripts, 2268 are DEGs (1286 downregulated shown in blue, 985 upregulated shown in red. The dysregulated MIGs are circled in yellow). (G) Differential gene expression analysis of MIGs compared to all transcripts. (H) Selection of significantly enriched canonical pathways identified by IPA analysis of all affected genes (DEGs plus IR and AS affected MIGs). -log (P) values > 1.3 (vertical line) signify significant enrichment. Significance was assessed by Fisher exact test. Source data are available online for this figure.CC BY · PubMed Central
Figure EV4 Analysis of cell proliferation and aberrant splicing of MIGs in A549 cells treated with siRNPC3 and siPDCD7 for 72 h. (A) Quantification of A549 cell growth over 72 h treatment with non-targeting (NT), two independent RNPC3 or 2 independent PDCD7 siRNAs. Data are represented as mean ± SEM (n = 3, 25 images per well, every hour). Significance was assessed by 2way ANOVA with Dunnett’s multiple comparisons test. Note: the siNT and siRNPC3 data are the same as shown in Fig. 5B. (B) RT-qPCR analysis of RNPC3 and PDCD7 mRNA in A549 cells after 72 h treatment with siRNAs. Data are represented as mean ± SEM (n = 3), significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. (C) RT-PCR analysis of example MIG splicing changes, identified in A549 cells treated with siRNPC3 or siPDCD7 for 72 h. Schematised IR and AS events are represented on the left with the minor intron in red and the flanking upstream and downstream exons in blue and orange, respectively. Exons not separated by a minor intron are grey.
Figure EV4 Analysis of cell proliferation and aberrant splicing of MIGs in A549 cells treated with siRNPC3 and siPDCD7 for 72 h. (A) Quantification of A549 cell growth over 72 h treatment with non-targeting (NT), two independent RNPC3 or 2 independent PDCD7 siRNAs. Data are represented as mean ± SEM (n = 3, 25 images per well, every hour). Significance was assessed by 2way ANOVA with Dunnett’s multiple comparisons test. Note: the siNT and siRNPC3 data are the same as shown in Fig. 5B. (B) RT-qPCR analysis of RNPC3 and PDCD7 mRNA in A549 cells after 72 h treatment with siRNAs. Data are represented as mean ± SEM (n = 3), significance was tested using a one-way ANOVA with Tukey’s multiple comparisons test. (C) RT-PCR analysis of example MIG splicing changes, identified in A549 cells treated with siRNPC3 or siPDCD7 for 72 h. Schematised IR and AS events are represented on the left with the minor intron in red and the flanking upstream and downstream exons in blue and orange, respectively. Exons not separated by a minor intron are grey.CC BY · PubMed Central
Figure EV5 RNAseq analysis of A549 cells treated with siRNPC3 for 72 h reveals defects in MIG splicing. (A) Heatmap of RNAseq identified MIG AS events. (B) Selected enriched GO terms of MIGs with significant intron retention. Significance was assessed by Welch’s t test. (C) Box plot of intron retention at minor introns and their upstream and downstream major introns. Significance was assessed by Mann–Whitney U test, n = 4 replicate RNAseq samples/genotype. (D, E) Transcriptome-wide IRFinder analysis showing median IR for all introns. (D) Major introns showing significantly upregulated IR (solid red circles) and significantly downregulated IR (solid blue circles). (E) Minor introns showing significantly upregulated IR (solid red circles). For an intron to be called as significantly retained in siRNPC3 samples, we required the following, FDR ЈQ 0.05, 100% coverage of the intron in siRNPC3 samples, 10% IRratio in siRNPC3 and 5% IRratio over NT samples. Likewise, for an intron to be significantly retained in NT samples, FDR ЈQ 0.05, 100% coverage across the intron in NT samples, 10% IRratio in NT cells and 5% IRratio over siRNPC3 samples. (F) Box plot of intron retention (% IRratio log10) across 234,057 major and 599 minor introns. Significance was assessed by paired t test.
Figure EV5 RNAseq analysis of A549 cells treated with siRNPC3 for 72 h reveals defects in MIG splicing. (A) Heatmap of RNAseq identified MIG AS events. (B) Selected enriched GO terms of MIGs with significant intron retention. Significance was assessed by Welch’s t test. (C) Box plot of intron retention at minor introns and their upstream and downstream major introns. Significance was assessed by Mann–Whitney U test, n = 4 replicate RNAseq samples/genotype. (D, E) Transcriptome-wide IRFinder analysis showing median IR for all introns. (D) Major introns showing significantly upregulated IR (solid red circles) and significantly downregulated IR (solid blue circles). (E) Minor introns showing significantly upregulated IR (solid red circles). For an intron to be called as significantly retained in siRNPC3 samples, we required the following, FDR ЈQ 0.05, 100% coverage of the intron in siRNPC3 samples, 10% IRratio in siRNPC3 and 5% IRratio over NT samples. Likewise, for an intron to be significantly retained in NT samples, FDR ЈQ 0.05, 100% coverage across the intron in NT samples, 10% IRratio in NT cells and 5% IRratio over siRNPC3 samples. (F) Box plot of intron retention (% IRratio log10) across 234,057 major and 599 minor introns. Significance was assessed by paired t test.CC BY · PubMed Central
Figure EV6 A549 cells treated for 72 h with RNPC3 siRNA exhibit differential expression of genes and MIGs that are enriched in cancer. (A) Heatmap of all identified differentially expressed MIGs, showing logCPM corrected for replicate and scaled for each gene. (B) Log-fold change plot of all MIGs highlighting those that exhibit significant changes in intron retention, differential expression or both when RNPC3 is knocked down.
Figure EV6 A549 cells treated for 72 h with RNPC3 siRNA exhibit differential expression of genes and MIGs that are enriched in cancer. (A) Heatmap of all identified differentially expressed MIGs, showing logCPM corrected for replicate and scaled for each gene. (B) Log-fold change plot of all MIGs highlighting those that exhibit significant changes in intron retention, differential expression or both when RNPC3 is knocked down.CC BY · PubMed Central
Figure 6 Minor class splicing knockdown induces DNA damage and cell cycle arrest in human cancer cell lines. (A) RT-PCR analysis of cell cycle related MIG splicing changes in A549 cells after 72 h treatment with 10 nM ASO. Schematic depictions of the obtained amplicons are shown on the right with the minor intron in red and the upstream and downstream exons coloured blue and orange, respectively. Exons not separated by a minor intron are grey. (B) Representative FACS plots of yH2AX expression from A549 cells after 72 h treatment with 10 nM ASO. (C) Quantification of yH2AX FACS analysis. Data are represented by the mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. (D) Two representative images of 53BP1 staining in A549 cells 72 h after 10 nM ASO treatment. Scale bar is 10 µm. (E) P53 immunoblot of nuclear and cytoplasmic fractions from A549 cells exposed to 10 nM ASO for 72 h (n = 3 biological replicates/condition). (F) Flow cytometry histograms of FITC senescence probe in A549 cells 72 h after 10 nM ASO treatment. (G) Quantification of senescence FACS analysis. MFI = median fluorescence intensity. Data are represented by mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. (H) Representative FACS plots of cell cycle analysis from A549 cells after 72 h treatment with 10 nM ASO. Proliferating cells stained for incorporated EdU against total DNA content measured by DAPI. (I) Quantification of FACS cell cycle analysis. Data are represented by mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. U12 ASO-treated samples were significantly different to NT ASO samples at two cell cycle stages: S P = 0.0009, G2 P < 0.0001. (J) Quantification of A549 cell growth over 72 h treatment across a titration of U12 ASO (0.625 nM–10 nM) compared to 10 nM non-targeted (NT) ASO. (K) Schematic diagram depicting the sequence of molecular and cellular events linking minor splicing disruption with reduced tumour burden. Data are represented as mean ± SEM (n = 4, 16 images per well, every hour). Source data are available online for this figure.
Figure 6 Minor class splicing knockdown induces DNA damage and cell cycle arrest in human cancer cell lines. (A) RT-PCR analysis of cell cycle related MIG splicing changes in A549 cells after 72 h treatment with 10 nM ASO. Schematic depictions of the obtained amplicons are shown on the right with the minor intron in red and the upstream and downstream exons coloured blue and orange, respectively. Exons not separated by a minor intron are grey. (B) Representative FACS plots of yH2AX expression from A549 cells after 72 h treatment with 10 nM ASO. (C) Quantification of yH2AX FACS analysis. Data are represented by the mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. (D) Two representative images of 53BP1 staining in A549 cells 72 h after 10 nM ASO treatment. Scale bar is 10 µm. (E) P53 immunoblot of nuclear and cytoplasmic fractions from A549 cells exposed to 10 nM ASO for 72 h (n = 3 biological replicates/condition). (F) Flow cytometry histograms of FITC senescence probe in A549 cells 72 h after 10 nM ASO treatment. (G) Quantification of senescence FACS analysis. MFI = median fluorescence intensity. Data are represented by mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. (H) Representative FACS plots of cell cycle analysis from A549 cells after 72 h treatment with 10 nM ASO. Proliferating cells stained for incorporated EdU against total DNA content measured by DAPI. (I) Quantification of FACS cell cycle analysis. Data are represented by mean ± SEM (n = 4). Significance was assessed by one-way ANOVA with Tukey’s multiple comparison test. U12 ASO-treated samples were significantly different to NT ASO samples at two cell cycle stages: S P = 0.0009, G2 P < 0.0001. (J) Quantification of A549 cell growth over 72 h treatment across a titration of U12 ASO (0.625 nM–10 nM) compared to 10 nM non-targeted (NT) ASO. (K) Schematic diagram depicting the sequence of molecular and cellular events linking minor splicing disruption with reduced tumour burden. Data are represented as mean ± SEM (n = 4, 16 images per well, every hour). Source data are available online for this figure.CC BY · PubMed Central
Figure EV7 A549 cells treated for 72 h with U12 ASO exhibit aberrant MIG splicing and markers of DNA damage. (A) RT-PCR analysis of MIG splicing changes in A549 cells after 72 h treatment with 10 nM ASO. Schematic depictions of the obtained amplicons are shown on the right with the minor intron in red and the upstream and downstream exons coloured blue and orange, respectively. Exons not separated by a minor intron are grey. (B) Representative images of γH2Ax (Ser139) staining in A549 cells 72 h after 10 nM ASO treatment. Scale bar is 10 µm.
Figure EV7 A549 cells treated for 72 h with U12 ASO exhibit aberrant MIG splicing and markers of DNA damage. (A) RT-PCR analysis of MIG splicing changes in A549 cells after 72 h treatment with 10 nM ASO. Schematic depictions of the obtained amplicons are shown on the right with the minor intron in red and the upstream and downstream exons coloured blue and orange, respectively. Exons not separated by a minor intron are grey. (B) Representative images of γH2Ax (Ser139) staining in A549 cells 72 h after 10 nM ASO treatment. Scale bar is 10 µm.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 13 Not checked · 127 Own results and interpretations

87 more claims

Create a free account to see all 140 claims and to verify the 20 references still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 12
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 68 references

Cited by

See all 6

Metadata

Authors
Doggett, K., Morgan, K. J., Olthof, A. M., Mieruszynski, S., Williams, B. B., Garnham, A. L., Milevskiy, M. J. G., Whitehead, L., Coates, J., Buchert, M., O’Donoghue, R. J. J., Hall, T. E., Putoczki, T. L., Ernst, M., Sutherland, K. D., Kanadia, R. N., & Heath, J. K.
Affiliations
  • The University of Melbourne (AU)
  • University of Copenhagen (DK)
  • Walter and Eliza Hall Institute of Medical Research (AU)
  • The University of Queensland (AU)
  • University of Connecticut (US)
Corresponding author
Heath, Joan K
Venue
EMBO Reports
Published
2025-07-07
Volume
26
Issue
15
Pages
3937-3969
ISSN
  • 1469-221X (ISSN-L)
  • 1469-3178
OpenAlex
W4412068648
Cited by
6
References
68
Citations by year
2026: 3 · 2025: 2
FWCI
0.97
Type
journal article
Language
en
Open access
Licence
Locations
  • EMBO Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (submittedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Australian Government Research Training Program Scholarship
  • National Institute of Neurological Disorders and Stroke (R01NS102538)
  • Federal Government | DHAC | National Health and Medical Research Council (1024878, 1161336)
  • Ludwig Institute for Cancer Research (N/A)
  • Victorian State Government Operational Support Grant (N/A)
  • Australian Government NHMRC Independent Research Institutes Infrastructure Support Scheme
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
minor spliceosome, cancer vulnerability, tumor growth inhibition, lung cancer, liver cancer, gastric cancer, replication stress, DNA damage, cell cycle arrest, apoptosis, gene expression profiling, mouse tumor model
MeSH terms
A549 Cells, Animals, DNA Damage, Humans, Introns, Neoplasms, RNA Splicing, Zebrafish, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, RNA-Binding Proteins, Apoptosis, Spliceosomes, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-11-22, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-22 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. https://app.cochat.ai/papers/10.1038/s44319-025-00511-8
The paper
Doggett, K., Morgan, K. J., Olthof, A. M., Mieruszynski, S., Williams, B. B., Garnham, A. L., Milevskiy, M. J. G., Whitehead, L., Coates, J., Buchert, M., O’Donoghue, R. J. J., Hall, T. E., Putoczki, T. L., Ernst, M., Sutherland, K. D., Kanadia, R. N., & Heath, J. K. (2025). Inhibition of the minor spliceosome restricts the growth of a broad spectrum of cancers. EMBO Reports. https://doi.org/10.1038/s44319-025-00511-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.